Perrigo Company plc
Every calculator, already run for PRGO
Open the full toolkit →You have the numbers on PRGO. Get the argument.
A written report on which of these readings actually decide the outcome for Perrigo Company plc, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
5 analysts covering PRGOAnalyst Price Target Disagreement for Perrigo Company plc
Wall Street's bull case implies +53% from the current price; the bear case implies +7%. A 46% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products,…
PRGO — frequently asked
Is PRGO a buy right now?
Wall Street's consensus rating on Perrigo Company plc is Buy across 5 analysts, with a mean price target of $16.50 (+27% vs. the current $13.04). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is PRGO overvalued?
PRGO trades at — trailing earnings, against a DCF fair value of $123 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is PRGO's next earnings date?
Perrigo Company plc is next scheduled to report earnings around Nov 4, 2026. A full PRGO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Perrigo Company plc?
Analysts covering Perrigo Company plc (PRGO) range from a bear-case target of $14.00 to a bull-case high of $20.00, with a mean consensus target of $16.50 across 4 analysts. The spread of $6.00 (46% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Perrigo Company plc against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Perrigo Company plc
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full PRGO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Perrigo Company plc, in minutes. 3 free reports included with every account — no credit card required.